Tesla
Dividend Calendar
Stock Rankings
ETF Rankings
Crypto Rankings
4.0
Tilray Inc. (TLRY) is a company operating in the cannabis and cannabinoid-based products industry. The company develops, cultivates, processes and distributes cannabis products for medical and consumer markets.
Its operations include a diversified portfolio of cannabis and related consumer products distributed across regulated markets.
Its main activities include:
• Cultivation and processing of medical and adult-use cannabis.
• Production of cannabis oils, dried flower and cannabinoid extracts.
• Development of CBD and hemp-based consumer products.
• Distribution of cannabis products through licensed medical and retail channels.
Tilray operates internationally with activities across North America, Europe and other regulated markets, supplying products through pharmacies, authorized distributors and retail networks where cannabis use is legally permitted.
Industry dynamics affecting the company include regulatory changes, expansion of legal cannabis markets, consumer demand for cannabis-based products and competition from other global cannabis producers.
Tilray Inc. trades on the Nasdaq under the ticker TLRY.
History and Development
Tilray Inc. was founded in 2013 in British Columbia, Canada, becoming one of the early licensed producers of medical cannabis under Canada’s regulatory framework.
The company expanded internationally during the mid-2010s, establishing operations and distribution channels in several regulated markets.
Tilray completed its initial public offering (IPO) in 2018 on the Nasdaq, becoming one of the first cannabis companies to list on a major U.S. exchange.
In 2021, Tilray merged with Aphria, creating one of the largest cannabis companies globally and expanding its production capacity and product portfolio.
Additional Information
Tilray Inc. (United States) is listed on the Nasdaq and has a market capitalization of $696.08 Millions, with shareholders equity totaling $1.53 Billion.
The company employs approximately 2.100 people and operates in the Health sector, within the Pharmaceutical Products industry.
Over the past 12 months, Tilray Inc. reported $858.27 Millions in revenue, generating net income of $-1.34 Billion.
Key financial metrics include a P/E ratio of -0.52, a price-to-book (P/B) ratio of 0.46, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker TLRY.
